192,000 Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Bought by TFG Asset Management GP Ltd

TFG Asset Management GP Ltd bought a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 192,000 shares of the biopharmaceutical company's stock, valued at approximately $4,852,000. Celldex Therapeutics makes up 1.0% of TFG Asset Management GP Ltd's holdings, making the stock its 19th largest position. TFG Asset Management GP Ltd owned about 0.29% of Celldex Therapeutics at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Celldex Therapeutics by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 3,881,995 shares of the biopharmaceutical company's stock worth $98,098,000 after acquiring an additional 12,213 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Celldex Therapeutics by 23.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company's stock worth $89,890,000 after acquiring an additional 676,771 shares during the period. Point72 Asset Management L.P. grew its holdings in shares of Celldex Therapeutics by 50.8% in the 4th quarter. Point72 Asset Management L.P. now owns 2,515,972 shares of the biopharmaceutical company's stock worth $63,579,000 after acquiring an additional 847,264 shares during the period. Deep Track Capital LP acquired a new stake in shares of Celldex Therapeutics in the 4th quarter worth approximately $38,919,000. Finally, Rock Springs Capital Management LP grew its holdings in shares of Celldex Therapeutics by 10.7% in the 4th quarter. Rock Springs Capital Management LP now owns 1,222,182 shares of the biopharmaceutical company's stock worth $30,885,000 after acquiring an additional 118,404 shares during the period.

Celldex Therapeutics Trading Down 2.4%

Shares of Celldex Therapeutics stock traded down $0.47 during trading hours on Friday, reaching $19.37. 320,116 shares of the company's stock were exchanged, compared to its average volume of 907,652. Celldex Therapeutics, Inc. has a 52-week low of $14.40 and a 52-week high of $47.00. The firm has a market capitalization of $1.29 billion, a price-to-earnings ratio of -7.54 and a beta of 1.39. The company has a fifty day moving average of $18.88 and a 200-day moving average of $22.23.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The business had revenue of $0.70 million for the quarter, compared to analysts' expectations of $1.08 million. On average, equities research analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on CLDX. UBS Group lowered their price target on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a report on Friday, May 9th. HC Wainwright reiterated a "buy" rating and set a $80.00 target price on shares of Celldex Therapeutics in a report on Tuesday, May 6th. Morgan Stanley lowered their target price on Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. Canaccord Genuity Group assumed coverage on Celldex Therapeutics in a report on Monday, April 28th. They set a "buy" rating and a $64.00 target price on the stock. Finally, The Goldman Sachs Group lowered their target price on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $53.90.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.